Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Page 1
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M, Bidel Z, Canoy D, Copland E, Bennett DA, Dehghan A, Davey Smith G, Holman RR, Woodward M, Gupta A, Adler AI, Wamil M, Sattar N, Cushman WC, McManus RJ, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration. Nazarzadeh M, et al. Lancet Diabetes Endocrinol. 2022 Sep;10(9):645-654. doi: 10.1016/S2213-8587(22)00172-3. Epub 2022 Jul 22. Lancet Diabetes Endocrinol. 2022. PMID: 35878651 Free PMC article.
Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute settings were excluded. ...
Trials exclusively on participants with heart failure or with short-term therapies and acute myocardial infarction or other acute set …
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials.
Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes AC, Salam A, Dwyer JP, Farzadfar F, Sundström J, Woodward M, Davis BR, Rahimi K; Blood Pressure Lowering Treatment Trialists' Collaboration; Blood Pressure Lowering Treatment Trialists Collaboration. Canoy D, et al. Heart. 2022 Jul 27;108(16):1281-1289. doi: 10.1136/heartjnl-2021-320171. Heart. 2022. PMID: 35058294 Free PMC article.
OBJECTIVE: Evidence from randomised trials of pharmacological treatments on long-term blood pressure (BP) reduction is limited. We investigated the antihypertensive drug effects on BP over time and across different participant characteristics. ...Appropriate treatment stra …
OBJECTIVE: Evidence from randomised trials of pharmacological treatments on long-term blood pressure (BP) reduction is limited. We in …
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
Blood Pressure Lowering Treatment Trialists' Collaboration. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2021 May 1;397(10285):1625-1636. doi: 10.1016/S0140-6736(21)00590-0. Lancet. 2021. PMID: 33933205 Free PMC article.
Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. ...
Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarc …
Cellular response to alkylating agent MNNG is impaired in STAT1-deficients cells.
Ah-Koon L, Lesage D, Lemadre E, Souissi I, Fagard R, Varin-Blank N, Fabre EE, Schischmanoff O. Ah-Koon L, et al. Among authors: fagard r. J Cell Mol Med. 2016 Oct;20(10):1956-65. doi: 10.1111/jcmm.12887. Epub 2016 Jul 27. J Cell Mol Med. 2016. PMID: 27464833 Free PMC article.
Using STAT1-proficient or -deficient cell lines, we found that STAT1 is required for: (i) reduction in the extent of DNA lesions, (ii) rapid phosphorylation of T68-CHK2 and of S15-p53, (iii) progression through the G2 /M checkpoint and (iv) long-term survival following tre …
Using STAT1-proficient or -deficient cell lines, we found that STAT1 is required for: (i) reduction in the extent of DNA lesions, (ii) rapid …
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, Gibbs JS, Huisman MV, Humbert M, Kucher N, Lang I, Lankeit M, Lekakis J, Maack C, Mayer E, Meneveau N, Perrier A, Pruszczyk P, Rasmussen LH, Schindler TH, Svitil P, Vonk Noordegraaf A, Zamorano JL, Zompatori M; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Konstantinides SV, et al. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283. Epub 2014 Aug 29. Eur Heart J. 2014. PMID: 25173341 Free article. No abstract available.
2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).
Erbel R, Aboyans V, Boileau C, Bossone E, Bartolomeo RD, Eggebrecht H, Evangelista A, Falk V, Frank H, Gaemperli O, Grabenwöger M, Haverich A, Iung B, Manolis AJ, Meijboom F, Nienaber CA, Roffi M, Rousseau H, Sechtem U, Sirnes PA, Allmen RS, Vrints CJ; ESC Committee for Practice Guidelines. Erbel R, et al. Eur Heart J. 2014 Nov 1;35(41):2873-926. doi: 10.1093/eurheartj/ehu281. Epub 2014 Aug 29. Eur Heart J. 2014. PMID: 25173340 Free article. No abstract available.
Reversible and irreversible differentiation of cardiac fibroblasts.
Driesen RB, Nagaraju CK, Abi-Char J, Coenen T, Lijnen PJ, Fagard RH, Sipido KR, Petrov VV. Driesen RB, et al. Among authors: fagard rh. Cardiovasc Res. 2014 Mar 1;101(3):411-22. doi: 10.1093/cvr/cvt338. Epub 2013 Dec 23. Cardiovasc Res. 2014. PMID: 24368833 Free PMC article.
Stress fibre de-polymerization could also be induced by mechanical strain release in p-MyoFb and non-p-MyoFb (2-day cultures in unrestrained 3-D collagen matrices). Only p-MyoFb showed true dedifferentiation after long-term 3-D cultures. CONCLUSIONS: Fb, p-MyoFb, and non-p …
Stress fibre de-polymerization could also be induced by mechanical strain release in p-MyoFb and non-p-MyoFb (2-day cultures in unrestrained …
Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial.
Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C. Peters R, et al. Among authors: fagard r. Eur Heart J. 2014 Jul;35(26):1712-8. doi: 10.1093/eurheartj/eht464. Epub 2013 Dec 2. Eur Heart J. 2014. PMID: 24302270 Free PMC article. Review.
Although the number of individuals reaching 80 who are considered to be healthy is increasing, the very elderly are likely to have long-term conditions, to report symptoms and/or be taking at least one regular medication. ...
Although the number of individuals reaching 80 who are considered to be healthy is increasing, the very elderly are likely to have long-t …
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), et al. Eur Heart J. 2012 Oct;33(20):2569-619. doi: 10.1093/eurheartj/ehs215. Epub 2012 Aug 24. Eur Heart J. 2012. PMID: 22922416 Free article. No abstract available.
Heart rate variability after heart transplantation: a 10-year longitudinal follow-up study.
Cornelissen VA, Vanhaecke J, Aubert AE, Fagard RH. Cornelissen VA, et al. Among authors: fagard rh. J Cardiol. 2012 Mar;59(2):220-4. doi: 10.1016/j.jjcc.2011.12.002. Epub 2012 Jan 21. J Cardiol. 2012. PMID: 22266458 Free article.
Our aim was to test this hypothesis by examining HRV in long-term longitudinal follow-up study of HTx recipients. METHODS AND RESULTS: 14 HTx recipients (11 men) were studied 1-48 (median 13) months (baseline) and 119-172 (median 141) months after HTx (follow-up). ...This …
Our aim was to test this hypothesis by examining HRV in long-term longitudinal follow-up study of HTx recipients. METHODS AND RESULTS …
78 results